Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Deals Business Strategies Rare Diseases

Ovid De-Risks Its Phase III Angelman Program With EU Angelini Partnership

  • News

Executive Summary

You may also be interested in...



Ovid Shifts Focus After Angelman Syndrome Drug Disappoints In Phase III

The Phase III clinical trial showed a noticeable placebo effect compared with OV101.

Takeda/Ovid Plan Phase III For Soticlestat In Dravet Syndrome, But Pull Back On LGS

A Phase II trial of the CH24H inhibitor showed a statistically significant benefit in children with the rare epilepsy syndrome Dravet Syndrome, but not in Lennox-Gastaut syndrome (LGS).

Tech Transfer Roundup: Tonix Inks Trio Of COVID-19-Focused Deals

New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.

Table

View full table

Related Content

Scrip

Topics

Related Companies

Tags:
Deals Business Strategies Rare Diseases
Latest News

Italfarmaco To Seek Givinostat Approvals After Phase III Success In DMD

Pfizer/BioNTech Bolster Case For Omicron Vaccines

Finance Watch: Venture Floodgates Open With New Funds, Dozens Of Rounds

Potential For Functional Cure Opens Up With GSK’s Hepatitis B Candidate

UsernamePublicRestriction

Register

SC142576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By